[1] FOSSELLA F.Randomized, multinational, phase Ⅲ study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer:the tax 326 study group[J].J Clin Oncol, 2003, 21(16):3016. doi: 10.1200/JCO.2003.12.046
[2] SIEGEL RL, MILLER KD, JEMAL A.Cancer statistics, 2015[J].CACA J Clin, 2015, 65(1):5. doi: 10.3322/caac.21254
[3] SIEGEL RL, MILLER KD, JEMAL A.Cancer statistics, 2016[J].CACA J Clin, 2016, 66(1):7. doi: 10.3322/caac.21332
[4] MILLER KD, SIEGEL RL, LIN CC, et al.Cancer treatment and survivorship statistics, 2016[J].CA J Clin, 2016, 66(4):271. doi: 10.3322/caac.21349
[5] SARA SF, FERNANDES JR PAULO CéSAR, BARBOSA SILVA MARCELO JOSé, et al.The neutrophil-to-lymphocyte ratio:a narrative review[J].Ecancermedicalscience, 2016, 10:702.
[6] MARCHIONI M, PRIMICERI G, INGROSSO M, et al.The clinical use of the neutrophil to lymphocyte ratio (nlr) in urothelial cancer:a systematic review[J].Clin Genitourin Cancer, 2016, 14(6):473. doi: 10.1016/j.clgc.2016.04.008
[7] MIYAMOTO R, INAGAWA S, SANO N, et al.Theneutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients[J].Eur J Surg Oncol, 2018, 44(5):607. doi: 10.1016/j.ejso.2018.02.003
[8] KITANO Y, YAMASHITA YI, YAKAMURA K, et al.Effects of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios on survival in patients with extrahepatic cholangiocarcinoma[J].Anticancer Res, 2017, 37(6):3229.
[9] YANG HJ, JIANG JH, LIU QA, et al.Preoperative platelet-to-lymphocyte ratio is a valuable prognostic biomarker in patients with hepatocellular carcinoma undergoing curative liver resection[J].Tumour Biol, 2017, 39(6):1010428317707375.
[10] YUAN C, LI N, MAO X, et al.Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer:Results from a large cohort[J].Thorac Cancer, 2017, 8(4):350. doi: 10.1111/1759-7714.12454
[11] IIMORI N, KASHIWAGI S, ASANO Y, et al.Clinical significance of the neutrophil-to-lymphocyte ratio in endocrine therapy for stage Ⅳ breast cancer[J].In Vivo, 2018, 32(3):669.
[12] ZHANG J, ZHANG HY, LI J, et al.The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer:a systematic review and meta-analysis[J].Oncotarget, 2017, 8(40):68837. doi: 10.18632/oncotarget.18575
[13] NISHINO M, JACKMAN DM, HATABU H, et al.New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non small cell lung cancer:comparison with original RECIST and impact on assessment of tumor response to targeted therapy[J].AJR Am J Roentgenol, 2010, 195(3):W221. doi: 10.2214/AJR.09.3928
[14] 张文, 张鹏, 徐雪莹, 等.中性粒细胞在肿瘤中作用的研究进展[J].肿瘤, 2017, 37(1):96. doi: 10.3969/j.issn.1672-4992.2017.01.026
[15] COFFELT SB, WELLENSTEIN MD, DE VISSER KE.Neutrophils in cancer:neutral nomore[J].Nat Rev Cancer, 2016, 16(7):431. doi: 10.1038/nrc.2016.52
[16] YAN W, XU H, WENYING X.Prognostic value of a novel scoring system using inflflammatory response biomarkers in non-small cell lung cancer:a retrospective study[J].Thorac Cancer, 2019, 10(6):1402. doi: 10.1111/1759-7714.13085
[17] VAN EGMOND M.BAKEMA JE.Neutrophils as effector cells for antibody-based immunotherapy of cancer[J].Semin Cancer Biol, 2013, 23(3):190. doi: 10.1016/j.semcancer.2012.12.002
[18] JIN H, ZHANG G, LIU X, et al.Blood neutrophil-lymphocyte ratio predicts survival for stages Ⅲ-Ⅳ gastric cancer treated with neoadjuvant chemotherapy[J].World J Surg Oncol, 2013, 11(1):12. doi: 10.1186/1477-7819-11-12
[19] BANAT GA, TRETYN A, PULLAMSETTI SS, et al.Immune and inflammatory cell composition of human lung cancer stroma[J].PLos One, 2015, 10(9):e0139073. doi: 10.1371/journal.pone.0139073
[20] DERMAN BA, MACKLIS JN, AZEEM MS, et al.Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer[J].BMC Cancer, 2017, 17(1):141. doi: 10.1186/s12885-017-3122-y
[21] WANG J, KALHOR N, HU J, et al.Pretreatment neutrophil to lymphocyte ratio is associated with poor survival in patients with stage i-iii non-small cell lung cancer[J].PLoS One, 2016, 11(10):e0163397. doi: 10.1371/journal.pone.0163397
[22] BAMBACE NM, HOLMES CE.The platelet contribution to cancer progression[J].J Thromb Haemost, 2011, 9(2):237. doi: 10.1111/j.1538-7836.2010.04131.x
[23] MORIMOTO K, SATOH-YAMAGUCHI K, HAMAGUCHI A, et al.Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs[J].Oncogene, 2008, 27(3):264. doi: 10.1038/sj.onc.1210645
[24] DIEM S, SCHMID S, KRAPF M, et al.Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab[J].Lung Cancer, 2017, 111:176. doi: 10.1016/j.lungcan.2017.07.024
[25] SONG XY, CHEN DW, MA Y, et al.Total lymphocyte count, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio as prognostic factors in advanced non-small cell lung cancer with chemoradiotherapy[J].Cancer Manag Res, 2018, 10:6677. doi: 10.2147/CMAR.S188578
[26] QIANG G, LIANG C, XIAO F, et al.Prognostic significance of platelet-to-lymphocyte ratio in non-small-cell lung cancer:a meta-analysis[J].Onco Targets Ther, 2016, 9:869.
[27] KANG KH, EFIRD JT, SHARMA N, et al.Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage Ⅲ non-small-cell lung cancer[J].Future Oncol, 2017, 13(16):1405. doi: 10.2217/fon-2017-0045
[28] PINATO DJ, SHINER RJ, SECKL MJ, et al.Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer[J].Br J Cancer, 2014, 110(8):1930. doi: 10.1038/bjc.2014.145
[29] LIU HB, WU Y, WANG ZF, et al.Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer[J].J Thorac Dis, 2013, 5(6):783.
[30] YAO Y, YUAN D, LIU H, et al.Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy[J].Cancer Immunol Immunother, 2013, 62(3):471. doi: 10.1007/s00262-012-1347-9
[31] 易福梅, 顾阳春, 陈森, 等.治疗前后NLR和PLR对进展期非小细胞肺癌一线化疗疗效及预后的预测价值[J].中国肺癌杂志, 2018, 21(6):481.